Kornimate/medical-research-clean huggingface dataset:
a study on the efficacy of androgen deprivation therapy combined with anti-pd-1 therapy in advanced lung cancer

Conditions: NSCLC, Stage III; NSCLC, Stage IV

Summary: androgen deprivation therapy (adt) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. anti-tumor synergism has been identified by combining adt with anti-pd-1 immunotherapy for androgen-independent tumors. this study is to investigate the combination of leuprorelin adt and sintilimab (anti-pd-1) therapy in patients with advanced lung cancer.

immune checkpoint blockades (icbs) are widely used in the clinical treatment of lung cancer. studies have shown that the quantity and function of tumor-infiltrating lymphocytes (tils) are associated with the effectiveness of pd-1 inhibitors in treating advanced nsclc. the thymus is crucial for the differentiation, development, and maturation of t cells. with age, thymic atrophy leads to immunosenescence, significantly affecting baseline anti-tumor immunity and responses to immunotherapies. preliminary findings have indicated that androgen deprivation therapy (adt) not only directly induces apoptosis in prostate cancer cells but also may exert anti-tumor effects by promoting thymic regeneration. furthermore, anti-tumor synergism has been identified by combining adt with anti-pd-1 immunotherapy for androgen-independent tumors. therefore, this study aims to investigate the combination of leuprorelin adt and sintilimab (anti-pd-1) therapy in patients with advanced lung cancer.

Eligibility criteria:
3.inclusion criteria: 1. male patients aged ≥60 years. 2. ecog performance status score of 0 \~1. 3. expected survival time of more than 3 months. 4. histologically or cytologically diagnosed advanced lung cancer according to the tnm staging system established by ajcc. 5. patients who have not previously received any anti-pd-1 treatment. 6. patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria. 7. at least one tumor lesion meeting the following criteria: * no prior local treatments such as radiotherapy * not biopsied during the screening period (if biopsy needed, baseline tumor assessment at least 14 days after the screening biopsy). * measurable at baseline (longest diameter of the lesion ≥10 mm; for a lymph node, short diameter ≥15 mm). * if only one measurable lesion, no prior local treatments such as radiotherapy. 8. ability to understand and voluntarily sign a written informed consent form. 9. willingness to follow the study protocol and follow-up examinations. exclusion criteria: * exclusion of cases that do not meet the inclusion criteria

Keywords: androgen deprivation therapy （adt） leuprorelin acetate nsclc pd-1 inhibitor
study of 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome

Conditions: Idiopathic Nephrotic Syndrome

Summary: the purpose of this study is to determine whether 7-valent pneumococcal conjugate vaccine safely induces immune responses and immunological memory in children with idiopathic nephrotic syndrome in remission.

idiopathic nephrotic syndrome (ins) is the most frequent glomerular disease in children under 16 years old with incidence rate 2-7/100,000 patients/year depending on ethnicity. those patients are susceptible to invasive pneumococcal disease (ipd) including peritonitis, pneumonia with or without pleural effusion and meningitis. due to increased mortality and risk of relapses associated with ipd, it has been recommended that children with ins should be immunized with pneumococcal conjugate vaccine \[1\]. however, concerns on vaccine safety and impaired immunogenicity due to ins pathogenesis and immunosuppressive treatment are a hurdle for universal implementation of existing guidelines. to thoroughly evaluate safety of 7-valent pneumococcal conjugate vaccine (pcv7) in children with ins in remission, we will investigate a possible association of vaccination with increased risk for recurrences of ins. we will also study immunogenicity and kinetics of immune response in ins patients and healthy subjects and the effect of different types of treatment on primary immune response and antibody persistence at 12-14 months following vaccination with pcv7.

Eligibility criteria:
inclusion criteria: * male or female * between 2-20 years of age exclusion criteria: * serious allergic reaction to previous vaccination * history of invasive pneumococcal disease * vaccination with pneumococcal conjugate vaccine * vaccination with pneumococcal polysaccharide vaccine * administration of intravenous immunoglobulin or other blood products during the last 3 months
loss of y chromosome in aortic stenosis

Conditions: Aortic Stenosis

Summary: the most common heart valve disease in humans is aortic stenosis which is a critical narrowing of the valve through which the heart has to pump blood to the rest of the body. this condition occurs in 2-3% of adults over 65 years of age and when it progresses to a severe stage leads to heart failure and need for valve replacement procedures (including surgery and catheter-based replacement). aortic stenosis has a strong male predominance. the purpose of this study is to evaluate whether loss of y-chromosome from circulating blood cells in males, which has been associated with tgf-beta-related fibrosis of other organs, is associated with the development of aortic stenosis.


Eligibility criteria:
inclusion criteria: * aortic stenosis (valve area \&lt;1.5cm2) exclusion criteria: * bicuspid aortic valve * history of radiation to chest * inflammatory (autoimmune, rheumatologic) disease associated with aortic stenosis * active cancer

Keywords: aortic stenosis y-chromosome transforming growth factor-beta echocardiography
prediction of acute kidney injury in patients with sepsis using venous excess ultrasound score

Conditions: Intensive Care Unit

Summary: sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. sepsis and septic shock are major healthcare problems, killing between one in three and one in six of those they affect. organ dysfunction can be represented by the sequential organ failure assessment (sofa) score of 2 points or more (respiratory rate of 22/min or greater, altered mentation, or systolic blood pressure of 100 mm hg or less), which is associated with an in- hospital mortality greater than 10%. septic shock is defined as a subset of sepsis in which profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mm hg or greater and serum lactate level greater than 2 mmol/l (\>18 mg/dl) in the absence of hypovolemia. this combination is associated with hospital mortality rates greater than 40%.

all patients with two out of four of systemic inflammatory response syndrome (sirs) criteria (heart rate greater than 90, respiratory rate greater than 20, temperature greater or equal to 38 ⁰ c or less than 36⁰ c, altered mental state) and suspected infection and one of the following risk factors ( age greater than 65 years, recent surgery immunocompromised aids, chemotherapy, neutropenia, diabetes, renal failure, hepatic failure, cancer, alcoholism)should be considered at risk of sepsis according to emergency department sepsis guidelines 2022. the vexus score ranges from grades 0-3. in grade 0, a non- dilated ivc (\ 2 cm. in grade 1, a dilated ivc and any combination of mildly abnormal flow patterns (but no severe features) indicates mild congestion. in grade 2, a dilated ivc and one severely abnormal flow pattern indicates moderate congestion. in grade 3, a dilated ivc and two or more severely abnormal flow patterns indicates severe congestion.

Eligibility criteria:
inclusion criteria: * all patients with sepsis. * patients aged between 21 and 65. * both sexes exclusion criteria: * patients refused to participate in the study. * renal failure. * right ventricular dysfunction and dilatation. * moderate to severe tricuspid regurge. * cases of cirrhosis with liver cell failure. * inadequate window. * ivc thrombus
development of tuberculosis diagnostic kit

Conditions: Tuberculosis; Lung Cancer; Pneumonia

Summary: pulmonary tuberculosis is one of the most important infectious diseases in human with high mortality. early diagnosis followed by antibiotic treatment is the only way for control of the disease. however, most of commercial tuberculosis diagnostic kits are of moderate sensitivity. oncoprobe inc. recently developed a tuberculosis diagnostic kit (hr-103) based on detection of antibody against mycobacterium tuberculosis in serum. the main purpose of this project is to evaluate the sensitivity and specificity of the kit in detection of pulmonary tuberculosis from saliva, urine, pleura and serum samples.capilia tb assay and another immunochromatographic assay such as esat-6 and cfp-10 based or other pcr based immunochromatographic assay will be tried to detection tuberculous disease.

sputum samples from 200 patients with chest or respiratory problems will be collected. presence of m. tuberculosis in the samples will be checked by acid-fast stain and bacterial culture and identification methods. at the same time, saliva, urine, and serum samples from these 200 patients and 50 healthy volunteers will be collected. the tuberculosis diagnostic kit (hr-103) from oncoprobe inc. or capilia tb assay or another immunochromatographic assay such as esat-6 and cfp-10 based or other pcr based immunochromatographic assay will be used to detect tuberculosis disease from these samples. by comparing the results with the stain and identification results of sputum samples from the 200 patients, the sensitivity and specificity of the kit in detection of pulmonary tuberculosis from saliva, urine,pleura and serum samples, as well as from combination of these samples, will be obtained. in addition to pulmonary tuberculosis, m. tuberculosis causes pleural tuberculosis. diagnosis of pleural tuberculosis involves determination of activities of adenosine deaminase and interferon-gamma in pleural effusion, which is tedious. we also plan to collect pleural effusion samples from 100 patients, and examined by the tuberculosis diagnostic kit (hr-103) from oncoprobe inc. by comparing the results with the adenosine deaminase and interferon-gamma activities of the same samples, the sensitivity and specificity of the kit in detection of pleural tuberculosis from pleural effusion samples will be obtained.

Eligibility criteria:
inclusion criteria: clinical suspicious of tuberculosis - exclusion criteria: * hiv

Keywords: diagnostic kit immunochromatography test pcr detection kit luminex
rapamune improves outcomes of severe h1n1 pneumonia

Conditions: H1N1 Pneumonia; Hypoxemia

Summary: severe h1n1 pneumonia with acute respiratory failure shows hyperactive immune cells infiltration of lung. rapamune, a mtor inhibitor, modulates the immune response by blocking activation of t- and b-cells. to investigate the clinical efficiency of rapamune in severe h1n1 pneumonia with respiratory failure, this study was conducted.

from 2009 winter to 2011 spring, patients with flu-like symptoms in chang gung memorial hospital were screened by rapid antigen test and influenza subtype was confirmed by polymerization chain reaction (pcr). 38 h1n1 patients with severe hypoxemia \[alveolar-arterial oxygen gradient, (a-a) o2 gradient, \> 200 mmhg\] requiring ventilator support were randomized to receive rapamune (2mg/day) or not. patients were then randomized to receive either sirolimus (rapamune 2mg/day, pfizer) or not for a course of 14 days. the outcome variables include liberation of ventilator, icu mortality, necessity of ecmo, sequential organ failure assessment (sofa) score and complications after admission to icu were recorded. sofa score composed of scores from six organ systems, graded from 0 to 4 according to the degree of dysfunction/failure.

Eligibility criteria:
inclusion criteria: * h1n1 patients with severe hypoxemia \[alveolar-arterial oxygen gradient, (a-a) o2 gradient, \> 200 mmhg\] requiring ventilator support were included to randomization. exclusion criteria: * severity of illness and multiple organ dysfunction (mod) were assessed within 24 hours of icu admission.

Keywords: h1n1 patients with severe hypoxemia requiring ventilator support
investigation of specific biomarkers in patients with atrial fibrillation who undergo interventional treatment

Conditions: Atrial Fibrillation

Summary: the two main mechanisms for atrial fibrillation (af) recurrence after cryoablation include pulmonary vein (pv) reconnection and the presence of non-pv associated arrhythmic focuses. the aim of this study is to reveal the specific biomarkers by antibody microarrays.

one hundred twenty patients with atrial fibrillation will participate in the study. they will be divided into three groups. 1. patients with af recurrence after the first procedure but with isolated pulmonary veins at the beginning of the second af ablation b)patients with af recurrence after repeat pv ablation. 2. patients with pv-associated atrial fibrillation. the group will be included patients with freedom of atrial fibrillation after pv isolation (first or repeat procedure). 3. healthy volunteers groups would be formed from patients who previously underwent atrial fibrillation ablations and whose blood samples have been taken and placed in a biobank before interventional treatment. the first step will include proteomic serum profiling using antibody microarrays in ten subjects will be split into 3 groups. the second step will include validation of selected protein biomarkers, in the total cohort (n=120).

Eligibility criteria:
inclusion criteria: • patient with paroxysmal/persistent atrial fibrillation who underwent interventional treatment exclusion criteria: * permanent af * contraindications to oral anticoagulation or heparin * chronic kidney disease requiring dialysis * untreated hypo- or hyperthyroidism * breast feeding * pregnancy * chronic kidney disease requiring dialysis * decompensated heart failure * stroke within the last 3 months * myocardial infarction within the last 3 months * percutaneous coronary intervention or coronary artery bypass grafting within the last 3 months * active myocarditis * artificial valve replacement surgery * severe mitral or aortic stenosis * coronary artery disease requiring revascularization * heart transplant

Keywords: atrial fibrillation protein microarray proteomic biomarkers pv dependent atrial fibrillation
reducing costs by deprescribing medications

Conditions: Polypharmacy; Deprescribing; Adverse Drug Reaction

Summary: the purpose of the study is to implement a pharmacist-led deprescribing intervention for adults 65 and older taking 10 or more medications at university of texas (ut) physicians clinics and to assess the effect of the pharmacist intervention on the incidence of adverse drug reactions, emergency room visits, and hospitalizations as well as costs to the patient and to the healthcare system in adults 65 and older taking 10 or more medications treated at ut physicians.


Eligibility criteria:
inclusion criteria: - taking 10 or more regular medications exclusion criteria: * not receiving primary care at ut physicians
a 52 week open label extension trial following the recurrence prevention study r076477-sch-301 to evaluate the safety and tolerability of paliperidone er in subjects with schizophrenia.

Conditions: Schizophrenia

Summary: the purpose of the study was an open label extension to the recurrence prevention study to evaluate long-term safety and tolerability of paliperidone er in subjects with schizophrenia.

the primary objective of the open-label extension was the long-term assessment of safety and tolerability of er oros paliperidone 3 to 15 mg/day in subjects diagnosed with schizophrenia. in addition, the long-term efficacy and effect of er oros paliperidone on overall functioning and personal and social functioning, as well as quality of life, health economics, and subjective sleep measures, was explored. this open-label extension study followed a recurrence prevention study (r076477-sch-301) that had both an open-label run-in/stabilization phase and a double-blind, placebo-controlled phase. open-label study drug (er oros paliperidone 3 mg to 15 mg/day) was administered for 52 weeks.

Eligibility criteria:
inclusion criteria: * subjects who had experienced a recurrence event during the double blind phase of study r076477-sch-301 * remained recurrence free until the end of the double-blind phase, or were in the run-in or stabilization phases when the study was terminated * who signed the informed consent for the open-label extension * and who the investigator agreed that open-label treatment was in the best interest of the subject were eligible to participate in the open-label extension exclusion criteria: * not eligible to enter the open-label phase if believed to be at significant risk for suicidal or violent behavior during the open-label extension trial * were pregnant or had received an injection of a depot antipsychotic since entry into the preceding double-blind phase

Keywords: paliperidone schizophrenia
neoadjuvant treatment of colon cancer

Conditions: Colon Cancer

Summary: this study will investigate * the effect of preoperative combination chemotherapy in patients with locally advanced colon cancer with mutation in the kras, braf or pik3ca gene * the effect of preoperative combination chemotherapy in combination with biological treatment in patients without mutation in the kras, braf or pik3ca gene.


Eligibility criteria:
inclusion criteria: * histologically verified locally advanced t3 or t4 colon cancer assessed by ct scan * analysis of kras, braf, pik3ca * age ≥18 år * performance status ≤ 2 * hematology * anc ≥ 1.5x10\^9/l. thrombocytes ≥ 100x10\^9/l. * biochemistry * bilirubinaemia ≤ 3 x unl. alat ≤ 5 x unl * consent to translational research * fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment. * written and orally informed consent. exclusion criteria: * clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease. * peripheral neuropathy nci grade \>1 * other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ * other investigational treatment within 30 days prior to treatment start * history of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest ct scan. * bleeding tumors * hypersensitivity to one or more of the substances

Keywords: colon cancer neoadjuvant treatment kras mutation braf mutation pik3ca mutation possibly avoid chemotherapy after operation
effect of rhythmic gymnastics training in children with down syndrome

Conditions: Physical Conditioning, Human

Summary: some of the clinical characteristics of people with down syndrome (ds) are orthopedic, cardiovascular, neuromuscular, visual, cognitive and perceptual disorders, which directly affect the quality of their movements. children with ds often have a sedentary lifestyle or low levels of physical activity which exacerbates problems related to obesity and overall physical health. therefore, the practice of physical exercise in this type of population is essential to improve their health-related physical fitness. the aim of this study was to analyze the influence of an adapted rhythmic gymnastics training program on body composition, tendon architecture and stiffness, and physical capacity in children with ds.

children with ds with medium to moderate intellectual disabilities are required to participate. participants will complete 10 weeks of training, two days per week. they will be divided into two groups: the control group will receive two swimming sessions per week and the experimental group will receive two swimming sessions plus two rhythmic gymnastics sessions. before and after the application of the program, the following will be evaluated: body composition by inbody 720, muscular architecture and elastography by logiq® s8 ultrasound scanner and tendon stiffness by myoton® pro portable myotonometer. the tendons to be studied will be the achilles tendon and the patellar tendon.

Eligibility criteria:
inclusion criteria: * disabiluty: mild to moderate exclusion criteria: * any contraindication to exercise * severe or profound intellectual disability * musculoskeletal disorders that prevented completion of the tests

Keywords: rhythmic gymnastics disability gymnastics training down syndrome child
bv-avd-r treatment children hodgkin's lymphoma

Conditions: Hodgkin Lymphoma

Summary: the goal of this clinical trial is to use modified brentuximab vedotin+doxorubicin+vinblastine+dacarbazine+rituximab(bv-avd-r) regimen in chinese classical hodgkin's lymphoma(hl) children. the main questions it aims to answer are: * \[overall response rate(orr) :complete response(cr)+partial response(pr)\] * \[progression-free survival (pfs), event-free survival (efs) and overall survival (os) at 6 months and 1 year.\] participants will be given modified bv-avd-r regimen according to rapid early responders (rer) or slow early responders (ser) after 2 cycles.

this study is a prospective study with period from october 2022 to december 2024, and planned to enroll 44 children with newly diagnosed intermediate- and high-risk classical hl. all patients will undergo positron emission tomography(pet)/computed tomography(ct) at the time of initial diagnosis and after 2 cycles of modified bv+r+avd regimen to determine early response. rapid early responders (rer) deﬁned as cr after 2 cycles of therapy. slow early responders (ser) defined as no cr (partial response (pr) or stable disease) after 2 cycles of therapy. intermediate-risk patients were stage ia bulk/e, ib, iia bulk/e, iib, and iiia. high-risk patients were stage iib bulk/e, iiia bulk/e, iiib, and iva/b. the primary endpoints include orr (cr+pr) and adverse events. the secondary endpoints include progression-free survival (pfs), event-free survival (efs) and overall survival (os) at 6 months and 1 year.

Eligibility criteria:
inclusion criteria: 1. age ≤ 18 years old, regardless of gender; 2. according to the who classification criteria in 2016, pathologically confirmed classic hodgkin's lymphoma is immunohistochemical cd30 positive; 3. newly diagnosed classic hodgkin's lymphoma: all stages 4. the main organs function normally and meet the following definitions: blood routine examination: neutrophil count ≥ 1.5 x 109/l, platelet count ≥ 75 x 109/l, hemoglobin count ≥ 80 g/dl; liver and kidney function: ast and alt ≤ 2.0 upper limit of normal values; bilirubin ≤ 2.0 mg/dl; creatinine clearance rate ≥ 60 ml/min; 5) functional status * for patients aged 1-16, the lansky score is ≥ 60 points. * for patients over 16 years old, the karnofsky score is ≥ 60 points. 6) previous treatment * except for emergency mediastinal irradiation (\<1000cgy) due to superior vena cava (svc) syndrome, hodgkin's lymphoma guidance treatment was not allowed before. 8) informed consent * patients or their legally authorized guardians must have a thorough understanding of their illness and the nature of the study (including foreseeable risks and possible adverse reactions), and must sign an informed consent form. exclusion criteria: 1. karnofsky\<60% or lansky\<60% for individuals under 16 years old. 2. children with hodgkin's lymphoma who have received other chemical and radiation treatments. 3. initially rated as low-risk pediatric classic hodgkin's lymphoma (ia, iia, without large masses)

Keywords: cd30 brentuximab vedotin children hodgkin lymphoma efficacy safety